Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Optic Nerve Sheath Meningioma Clinical Presentation

  • Author: Mitchell V Gossman, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: May 18, 2016
 

History

The characteristic profile of a compressive optic neuropathy, such as that caused by ONSM, is usually painless, chronic progressive visual loss that may be accompanied by proptosis.

Transient visual obscurations also have been reported; however, this phenomenon is not a specific feature, as it has been observed in patients with optic disc swelling resulting from other causes.

Age of presentation varies widely, ranging from 3-76 years across all series. In several series, the incidence of visual loss as the presenting feature was more common than proptosis, even though in some series with more ophthalmologic detail, the presentation of proptosis was greater than visual loss. Presentation with either symptom complex is about equal.

Cases may be bilateral (approximately 6%).

An important macroscopic variant of ONSM is the en plaque meningioma (EPM), which is not greatly raised above the level of dura mater. This type of meningioma grows within the meningeal sheath and expands the meninges without forming large exophytic masses. It is prone to invade adjacent bone with accompanying hyperostosis. This group of meningiomas essentially infiltrates the brain and the orbit, mainly via natural apertures (eg, foramina, fissures) and through the passageway of perforating blood vessels, which are increased in number.

Hyperostosis is present in 44% of cases, but it is not a specific finding. EPM typically occurs at the base of the skull, especially within the sphenoid ridge. Clinical presentation depends on the site or extent of the tumor. Patients with juxtaorbital EPM often present with visual complaints. In a series in 1982, Pompili et al reported 33 of 49 cases of EPMs in a series of hyperostosis meningiomas of the sphenoid ridge.[6] Clinical symptoms were not different between the various histopathological types (ie, no difference was seen clinically between EPM and the globular type of hyperostosis meningiomas of the sphenoid).

Common symptoms include the following:

Common neurologic complaints include the following:

  • Unilateral optic atrophy or subatrophy (29%)
  • Decreased visual acuity (24%)
  • Oculomotor disturbance (21%)

Hyperostosis and/or endostosis are common with meningiomas. Hyperostotic meningiomas are viewed as disease of the bone. Globular meningiomas, which are associated with bony reaction and invasion, are referred to as en masse (global) meningiomas.

Next

Physical

The presentation of optic nerve sheath meningioma (ONSMs) largely depends on whether they arise from the orbit, within the optic canal, or intracranially. Notwithstanding, the classic triad of ONSM is visual loss, optic atrophy, and optociliary shunt vessels.

The characteristic symptom and sign of ONSM is very slow visual loss with preservation of the central visual field for years.

The presence of an optociliary venous shunt on the disc,[7] if associated with disc pallor or visual loss, is suggestive but not pathognomonic of ONSM. These vessels are more appropriately termed retinochoroid venous collaterals and arise from chronic compression of the central retinal vein. These blood vessels shunt blood into choroidal venous circulation. Optociliary shunts result from meningiomas arising from the optic nerve sheath or from spheno-orbital meningiomas. They can occur with other types of tumors (eg, optic nerve gliomas) and chronic papilledema, but they occur most frequently from old central retinal vein occlusion.

Optic disc pallor and swelling have been reported equally in different series. If there is disc edema, the tumor is at least partially intraorbital.

Disturbance of ocular motility was mainly reported by Sibony et al in one series of 47 patients.[8]

Previous
Next

Causes

A common etiology for meningiomas is radiation exposure in the range of 132-315 roentgens, which is equivalent to the rad dose of 1-3 Gy. Characteristics of radiation-induced meningiomas include an average latent period of 36-38 years for patients who were exposed to low-dose radiation to the head, whereas patients who develop meningiomas after exposure to high-dose radiation may show signs as early as 5 years postradiation.[9]

In general, radiation-induced meningiomas occur more frequently over the convexities (ie, in about 80% of cases). They have a more frequent recurrence rate, and they exhibit malignant behavior that is also indicated histologically by hypercellularity and pleomorphism.

Head trauma used to be considered a possible risk factor, but recent large studies do not support this association.

Hereditary predisposition

Another factor that has been studied is hereditary predisposition.

Loss of DNA on chromosome 22 has been shown in 40% of meningiomas.

In cytogenetic studies, genetic abnormalities at the level of chromosome 22 are seen frequently in meningiomas with the loss of a copy of chromosome 22 as the most commonly reported abnormality.

Monosomy of chromosome 22 has been reported to occur in 70-80% of meningiomas.

Abnormalities of chromosome 22 have been associated with type II neurofibromatosis.

Hormonal factors

Hormonal factors, such as estrogen and progesterone, have been studied extensively as risk factors for meningiomas because of the striking predominance of meningiomas in women. Other evidence to substantiate the implication of gender-specific hormones comes from data showing increased growth of meningiomas during pregnancy and size changes with menses. Initially, interest was focused on estrogen because it had been reported in one comprehensive review by McCutcheon that 30% of meningiomas have estrogen receptors; however, no further studies were conducted, and interest became focused on other hormones (ie, progesterone).[10]

The progesterone receptor is the most likely candidate as an etiology for meningiomas. Progesterone receptors have been shown to be expressed in 81% of women and in 40% of men with meningiomas. Other studies indicate that progesterone binds to meningiomas in 50-100% of tested specimens; however, most reports show binding in the higher end of this range. No relation has been found between progesterone receptor status and age, sex, tumor location, or menopausal state. These findings have prompted researchers to develop antiprogesterone medications, such as mifepristone (RU-486), which appear to inhibit tumor growth in vitro and in vivo.

Androgen receptors have been found in 40-100% of meningiomas studied in several studies, but their receptor expression is variable, making them less likely candidates in the pathophysiology of meningiomas. Meningiomas vary in expression of receptors for other hormones (eg, epidermal growth factor [EGF], platelet derived growth factor [PDGF], fibroblast growth factor), which makes them less likely candidates for oncogenesis of meningiomas. It has been suggested that the direct stimulatory effect of EGF on PDGF or PDGF itself may be partially responsible for angiogenesis and even oncogenesis in meningiomas. PDGF is a particularly attractive candidate because it has structural homology with the product of c-sis oncogene on chromosome 22. Infectious agents that have been associated with meningiomas include simian vacuolating virus 40 (SV-40) and adenovirus.

Previous
 
 
Contributor Information and Disclosures
Author

Mitchell V Gossman, MD Partner and Vice President, Eye Surgeons and Physicians, PA; Medical Director, Central Minnesota Surgical Center; Clinical Associate Professor, University of Minnesota Medical School

Mitchell V Gossman, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, Minnesota Medical Association, North American Neuro-Ophthalmology Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

Coauthor(s)

Sally B Zachariah, MD Associate Professor, Department of Neurology, University of South Florida College of Medicine; Director, Department of Neurology, Division of Strokes, Veteran Affairs Medical Center of Bay Pines

Sally B Zachariah, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Society of Neuroimaging

Disclosure: Partner received none from none for none.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Andrew W Lawton, MD Neuro-Ophthalmology, Ochsner Health Services

Andrew W Lawton, MD is a member of the following medical societies: American Academy of Ophthalmology, Arkansas Medical Society, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Suzan Khoromi, MD Fellow, Pain and Neurosensory Mechanisms Branch, National Institute of Dental and Cranial Research, National Institutes of Health

Suzan Khoromi, MD is a member of the following medical societies: American Academy of Neurology, American Pain Society, and International Association for the Study of Pain

Disclosure: Nothing to disclose.

Brian R Younge, MD Professor of Ophthalmology, Mayo Clinic School of Medicine

Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

References
  1. Cushing H, Eisenhardt L. Meningiomas: their classification, regional behaviour, life history, and surgical end results. Springfield, Ill: Charles Thomas; 1938.

  2. Coke CC, Corn BW, Werner-Wasik M, Xie Y, Curran WJ Jr. Atypical and malignant meningiomas: an outcome report of seventeen cases. J Neurooncol. 1998 Aug. 39(1):65-70. [Medline].

  3. Menon G, Nair S, Sudhir J, Rao BR, Mathew A, Bahuleyan B. Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir (Wien). 2009 Mar. 151(3):239-44; discussion 244. [Medline].

  4. Harold Lee HB, Garrity JA, Cameron JD, Strianese D, Bonavolontà G, Patrinely JR. Primary optic nerve sheath meningioma in children. Surv Ophthalmol. 2008 Nov-Dec. 53(6):543-58. [Medline].

  5. Sheikh BY, Siqueira E, Dayel F. Meningioma in children: a report of nine cases and a review of the literature. Surg Neurol. 1996 Apr. 45(4):328-35. [Medline].

  6. Pompili A, Derome PJ, Visot A, Guiot G. Hyperostosing meningiomas of the sphenoid ridge--clinical features, surgical therapy, and long-term observations: review of 49 cases. Surg Neurol. 1982 Jun. 17(6):411-6. [Medline].

  7. Boschetti NV, Smith JL, Osher RH, Gass JD, Norton EW. Fluorescein angiography of optociliary shunt vessels. J Clin Neuroophthalmol. 1981 Mar. 1(1):9-30. [Medline].

  8. Sibony PA, Krauss HR, Kennerdell JS, Maroon JC, Slamovits TL. Optic nerve sheath meningiomas. Clinical manifestations. Ophthalmology. 1984 Nov. 91(11):1313-26. [Medline].

  9. Chacko JG, Schatz NJ, Glaser JS. Delayed optic nerve complications after proton beam irradiation. Ann Ophthalmol (Skokie). 2008 Fall-Winter. 40(3-4):166-70. [Medline].

  10. McCutcheon IE. The biology of meningiomas. J Neurooncol. 1996 Sep. 29(3):207-16. [Medline].

  11. Ing EB, Garrity JA, Cross SA, Ebersold MJ. Sarcoid masquerading as optic nerve sheath meningioma. Mayo Clin Proc. 1997 Jan. 72(1):38-43. [Medline].

  12. [Guideline] Zimmerman RD, Seidenwurm DJ, Davis PC, Brunberg JA, De La Paz RL, Dormont PD, et al. Orbits, vision, and visual loss. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. [Full Text].

  13. Miller NR. New concepts in the diagnosis and management of optic nerve sheath meningioma. J Neuroophthalmol. 2006 Sep. 26(3):200-8. [Medline].

  14. Milker-Zabel S, Huber P, Schlegel W, Debus J, Zabel-du Bois A. Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neurooncol. 2009 Apr 1. [Medline].

  15. Arvold ND, Lessell S, Bussiere M, Beaudette K, Rizzo JF, Loeffler JS, et al. Visual Outcome and Tumor Control After Conformal Radiotherapy for Patients With Optic Nerve Sheath Meningioma. Int J Radiat Oncol Biol Phys. 2009 Apr 28. [Medline].

  16. Smee RI, Schneider M, Williams JR. Optic nerve sheath meningiomas--non-surgical treatment. Clin Oncol (R Coll Radiol). 2009 Feb. 21(1):8-13. [Medline].

  17. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985 Jan. 62(1):18-24. [Medline].

  18. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery. 1987 Apr. 20(4):525-8. [Medline].

  19. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys. 1990 Apr. 18(4):755-61. [Medline].

  20. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci. 1997 Nov. 24(4):302-6. [Medline].

  21. Greenberg HS. Meningiomas. Gilman S, Goldstein GW, Waxman SG. Neurobase. 1st ed. Arbor Publishing: San Diego; 1998.

  22. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991 Jun. 74(6):861-6. [Medline].

  23. De Monte F. Current management of meningiomas. Oncology (Williston Park). 1995 Jan. 9(1):83-91, 96; discussion 96, 99-101. [Medline].

  24. Black P, Kathiresan S, Chung W. Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Acta Neurochir (Wien). 1998. 140(10):1013-6; discussion 1016-7. [Medline].

  25. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996 Mar 1. 34(4):817-22. [Medline].

  26. Akeyson EW, McCutcheon IE. Management of benign and aggressive intracranial meningiomas. Oncology (Williston Park). 1996 May. 10(5):747-56; discussion 756-9. [Medline].

  27. Donnell MS, Meyer GA, Donegan WL. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg. 1979 Apr. 50(4):499-502. [Medline].

  28. Finn JE, Mount LA. Meningiomas of the tuberculum sellae and planum sphenoidale. A review of 83 cases. Arch Ophthalmol. 1974 Jul. 92(1):23-7. [Medline].

  29. Firsching RP, Fischer A, Peters R, Thun F, Klug N. Growth rate of incidental meningiomas. J Neurosurg. 1990 Oct. 73(4):545-7. [Medline].

  30. Kennerdell JS, Maroon JC, Malton M, Warren FA. The management of optic nerve sheath meningiomas. Am J Ophthalmol. 1988 Oct 15. 106(4):450-7. [Medline].

  31. Kinjo T, Mukawa J, Koga H, Shingaki T. An extensive cranial base meningioma extending bilaterally into Meckel's cave: case report. Neurosurgery. 1997 Mar. 40(3):615-7; discussion 617-8. [Medline].

  32. Kyritsis AP. Chemotherapy for meningiomas. J Neurooncol. 1996 Sep. 29(3):269-72. [Medline].

  33. Langford LA. Pathology of meningiomas. J Neurooncol. 1996 Sep. 29(3):217-21. [Medline].

  34. Lee AG, Woo SY, Miller NR, Safran AB, Grant WH, Butler EB. Improvement in visual function in an eye with a presumed optic nerve sheath meningioma after treatment with three-dimensional conformal radiation therapy. J Neuroophthalmol. 1996 Dec. 16(4):247-51. [Medline].

  35. Lloyd GA. Primary orbital meningioma: a review of 41 patients investigated radiologically. Clin Radiol. 1982 Mar. 33(2):181-7. [Medline].

  36. Mafee MF, Goodwin J, Dorodi S. Optic nerve sheath meningiomas. Role of MR imaging. Radiol Clin North Am. 1999 Jan. 37(1):37-58, ix. [Medline].

  37. Maor MH. Radiotherapy for meningiomas. J Neurooncol. 1996 Sep. 29(3):261-7. [Medline].

  38. Maroon JC, Kennerdell JS. Optic nerve sheath meningioma. Arch Neurol. 1981 May. 38(5):326. [Medline].

  39. Nakagawa H, Lusins JO. Biplane computed tomography of intracranial meningiomas with extracranial extension. J Comput Assist Tomogr. 1980 Aug. 4(4):478-83. [Medline].

  40. Russel DS, Rubinstein LJ. Russell and Rubinstein's Pathology of Tumors of the Nervous System. Bigner DD, McLendon RE, Bruner JM, eds. Hodder Headline Group. Vol. 1:1998.

  41. Schlehofer B, Blettner M, Wahrendorf J. Association between brain tumors and menopausal status. J Natl Cancer Inst. 1992 Sep 2. 84(17):1346-9. [Medline].

  42. Zimmerman RA. Imaging of intrasellar, suprasellar, and parasellar tumors. Semin Roentgenol. 1990 Apr. 25(2):174-97. [Medline].

 
Previous
Next
 
Meningioma of the orbit. Axial sequence on T1-weighted MRI with gadolinium that shows enhancing lesion of the orbit causing proptosis and en plaque invagination laterally around the temporal pole and medially above the ethmoid sinus.
Meningioma of the optic nerve sheath. Coronal section of T1-weighted MRI of the orbits that shows a left orbital mass lesion occupying most of the orbital lumen, diffusely enhancing with gadolinium.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.